San Diego, CA -- (SBWire) -- 10/24/2016 --Certain directors of Rigel Pharmaceuticals are under investigation over potential wrongdoing. The investigation was announced on behalf of current long-term investors in NASDAQ:RIGL shares concnering potential breaches of fiduciary duties by certain directors at Rigel Pharmaceuticals.
Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Rigel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Rigel Pharmaceuticals, Inc. reported that its annual Total Revenue increased from $8.25 million in 2014 to $28.89 million in 2015 and that its Net Loss declined from $90.91 million in 2014 to $51.46 million in 2015. Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) grew from $2.13 per share in July 2016 to as high as $4.11 per share on October 5, 2016.
On October 20, 2016, Rigel Pharmaceuticals, Inc. reported results from the second FIT phase 3 study and the long-term open-label extension study for Fostamatinib in adult chronic/persistent immune thrombocytopenia (ITP). Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) declined to as low as $1.95 per share on October 20, 2016.
On October 21, 2016, NASDAQ:RIGL shares closed at $2.59 per share.
Those who purchased shares of Rigel Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Rigel Pharmaceuticals, Inc. (RIGL) Under Investigation for Investors over Potential Wrongdoing by Certain Directors
An investigation on behalf of investors in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares over potential wrongdoing at Rigel Pharmaceuticals, Inc. was announced and NASDAQ:RIGL stockholders should contact the Shareholders Foundation.